HomeLONN • SWX
add
Lonza Group AG
Previous close
CHF 554.00
Year range
CHF 354.30 - CHF 589.40
Market cap
40.01B CHF
Avg Volume
150.56K
P/E ratio
69.81
Dividend yield
0.72%
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.53B | -0.68% |
Operating expense | 282.50M | 10.78% |
Net income | 164.50M | -19.76% |
Net profit margin | 10.76 | -19.22% |
Earnings per share | — | — |
EBITDA | 412.00M | -8.34% |
Effective tax rate | 16.46% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.02B | -6.10% |
Total assets | 17.88B | 1.20% |
Total liabilities | 8.47B | 16.00% |
Total equity | 9.41B | — |
Shares outstanding | 71.37M | — |
Price to book | 4.23 | — |
Return on assets | 3.85% | — |
Return on capital | 5.21% | — |
Cash Flow
Net change in cash
| (CHF) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 164.50M | -19.76% |
Cash from operations | 252.50M | 36.86% |
Cash from investing | -527.50M | -141.97% |
Cash from financing | 237.00M | 10.23% |
Net change in cash | -35.50M | -119.78% |
Free cash flow | -182.56M | 12.81% |
About
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector. Wikipedia
Founded
1897
Headquarters
Website
Employees
17,834
